Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-11.1%
5Y CAGR+15.3%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-11.1%/yr
vs +90.0%/yr prior
5Y CAGR
+15.3%/yr
Recent deceleration
Acceleration
-101.0pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$21.56M-24.9%
2024$28.72M-0.6%
2023$28.88M-5.8%
2022$30.65M+13.7%
2021$26.96M+154.6%
2020$10.59M+176.4%
2019$3.83M+62.7%
2018$2.35M-